Abstract: Objective The aim of this study was to investigate entecavir (ETV) antiviral treatment with daily outcutaneous irradiation of infrared ray in patients with hepatitis B-induced liver cirrhosis (LC). Methods 84 patients with LC due to hepatitis B viral infection were encountered in our hospital between January 2021 and January 2024, and were randomly assigned to receive oral ETV (control, n＝42) or ETV with daily outcutaneous irradiation of infrared ray by a bio-informational infrared liver disease therapist (observation, n＝42). All patients were followed-up for three months. Serum HBV markers and HBV DNA loads were routinely detected. Serum hyaluronic acid (HA), laminin (LN), type Ⅲ procollagen (PⅢ-P) and collage type Ⅳ(Ⅳ-C) levels were detected by RIA. Serum transforming growth factor beta 1 (TGF-β1) , interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) levels were assayed by ELISA. Splenic vein diameter (SVD) and portal vein diameter (PVD), and portal vein flow velocity (PVFV) were determined by ultrasonography. Results By end of three month observation, serum HA, PⅢ-P and Ⅳ-C levels in the observation group were(102.2±10.3)mg/L, (114.2±11.5)ng/mL and (71.2±7.3)ng/mL, all significantly lower than [(134.0±11.5)mg/L, (152.7±13.8)ng/mL and (89.1±9.2)ng/mL, respectively, P＜0.05] in the control; serum TGF-β1, IL-6 and TNF-α levels were (20.3±3.9)ng/mL, (17.0±2.6)ng/mL and (21.4±3.1)ng/mL, all significantly lower than [(31.4±4.1)ng/mL, (24.3±3.0)ng/mL and (33.5±4.2)ng/mL, respectively, P＜0.05] in the control group; there were no significant differences as respect to liver function index, serum HBsAg and HBeAg, serum HBV DNA loads, and portal vein parameters between the two groups (P>0.05). Conclusion Entecavir antiviral treatment with auxiliary infrared ray irradiation could inhibit liver fibrosis progression, which might be related to modulation of cytokine metabolism.

Key words: Liver cirrhosis, Hepatitis B, Entecavir, Bio-informational infrared iiver disease therapist, Therapy